Kala Pharmaceuticals Inc - Asset Resilience Ratio
Kala Pharmaceuticals Inc (KALA) has an Asset Resilience Ratio of 14.92% as of June 2023. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read KALA liabilities breakdown for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2021)
This chart shows how Kala Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. See KALA total equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Kala Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see how much is Kala Pharmaceuticals Inc worth.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $9.92 Million | 14.92% |
| Total Liquid Assets | $9.92 Million | 14.92% |
Asset Resilience Insights
- Moderate Liquidity: Kala Pharmaceuticals Inc has 14.92% of assets in liquid form.
- While adequate for normal operations, this level may limit flexibility during economic stress.
- The company has significant short-term investments, indicating active treasury management.
Kala Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio
Compare Kala Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 3.28% |
|
Summit Therapeutics PLC
NASDAQ:SMMT |
Biotechnology | 0.00% |
|
Argen-X
F:1AE |
Biotechnology | 25.67% |
|
Zhejiang Ausun Pharmaceutical Co Ltd
SHG:603229 |
Biotechnology | 0.21% |
|
R&G PharmaStudies Co. Ltd. A
SHE:301333 |
Biotechnology | 35.96% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.48% |
|
Innovita Biological Technology Co. Ltd. A
SHG:688253 |
Biotechnology | 70.49% |
|
Sunmax Biotechnology Co Ltd
TWO:4728 |
Biotechnology | 10.53% |
Annual Asset Resilience Ratio for Kala Pharmaceuticals Inc (2017–2021)
The table below shows the annual Asset Resilience Ratio data for Kala Pharmaceuticals Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2021-12-31 | 0.00% | $0.00 | $139.43 Million | -- |
| 2020-12-31 | 34.42% | $76.28 Million | $221.61 Million | +33.97pp |
| 2019-12-31 | 0.45% | $699.00K | $154.32 Million | -- |
| 2017-12-31 | 0.00% | $0.00 | $116.13 Million | -- |
About Kala Pharmaceuticals Inc
KALA BIO, Inc. a clinical-stage biopharmaceutical company, engages in the research, development, and commercialization of therapies for rare and severe eye diseases. The company's lead product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; and limbal stem cell deficiency and other rare corneal diseases. Its preclinical d… Read more